8-K: Global Medical REIT Reports Q3 Loss, Higher Debt

Global Medical REIT Inc. reported a net loss of $6.0 million for Q3 2025, or $0.45 per diluted share, a significant decline from net income in the prior year, alongside increased debt and an impairment charge.

Summary

• Net loss attributable to common stockholders for Q3 2025 was approximately $6.0 million, or $0.45 per diluted share, compared to net income of $1.8 million, or $0.14 per diluted share, in Q3 2024.
• For the nine months ended September 30, 2025, net loss attributable to common stockholders was approximately $4.7 million, or $0.35 per diluted share, compared to a net loss of $0.6 million, or $0.04 per diluted share, in the prior year period.
• Third quarter 2025 same-store cash net operating income (NOI) growth was 2.7% year-over-year.
• Net Debt / Annualized Adjusted EBITDAre increased to 6.9x as of September 30, 2025, from 6.5x in the comparable prior year period.
• The portfolio was 95.2% occupied, comprising 5.2 million leasable square feet with an annualized base rent of approximately $118.4 million as of September 30, 2025.
• An impairment of investment property of $6.281 million was recorded in Q3 2025.

Sentiment

Score: 3

Explanation: The significant net loss, driven by a property impairment, and increased leverage are strong negative indicators. While operating metrics like same-store NOI growth and occupancy are positive, they are overshadowed by the financial performance decline and increased debt burden. The overall sentiment is negative due to the unexpected loss and higher leverage.

Positives

• Same-store cash net operating income (NOI) grew by 2.7% year-over-year in Q3 2025.
• Portfolio occupancy remains strong at 95.2% as of September 30, 2025.
• EBITDAre increased to $24.224 million in Q3 2025 from $22.446 million in Q3 2024.
• Adjusted EBITDAre increased to $25.714 million in Q3 2025 from $24.002 million in Q3 2024.
• NOI increased to $29.005 million in Q3 2025 from $26.827 million in Q3 2024.
• Cash NOI increased to $28.786 million in Q3 2025 from $26.608 million in Q3 2024.
• Same-store cash NOI increased to $25.292 million in Q3 2025 from $24.639 million in Q3 2024.

Negatives

• Reported a net loss attributable to common stockholders of $6.0 million, or $0.45 per diluted share, for Q3 2025, a significant decline from net income of $1.8 million, or $0.14 per diluted share, in Q3 2024.
• Reported a net loss attributable to common stockholders of $4.7 million, or $0.35 per diluted share, for the nine months ended September 30, 2025, compared to a net loss of $0.6 million, or $0.04 per diluted share, in the prior year period.
• Net Debt / Annualized Adjusted EBITDAre increased to 6.9x as of September 30, 2025, from 6.5x in the comparable prior year period, indicating higher leverage.
• Total Gross Debt increased to $712.853 million as of September 30, 2025, from $634.324 million as of September 30, 2024.
• Net Debt increased to $705.730 million as of September 30, 2025, from $628.601 million as of September 30, 2024.
• An impairment of investment property of $6.281 million was recognized in Q3 2025, contributing to the net loss.
• Net Debt + Preferred / Annualized Adjusted EBITDAre increased to 7.6x as of September 30, 2025, from 7.3x in the comparable prior year period.

Risks

• A significant portion of leases are expiring in the near to medium term, with 11.1% of Annualized Base Rent (ABR) expiring in 2026, 10.7% in 2027, and 16.1% in 2029, potentially exposing the company to re-leasing risk or market rent fluctuations.
• Increased leverage ratios (Net Debt / Annualized Adjusted EBITDAre at 6.9x and Net Debt + Preferred / Annualized Adjusted EBITDAre at 7.6x) could pose a risk in a rising interest rate environment or economic downturn.
• The recognition of a $6.281 million impairment of investment property suggests potential issues with asset valuation or performance.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the current reporting period. It notes that the annualized base rent methodology used does not account for future contractual rental rate increases, leasing activity, or lease expirations.

Industry Context

The medical real estate sector, particularly outpatient facilities, generally benefits from an aging population and the shift towards more cost-effective care settings outside traditional hospitals. Global Medical REIT's portfolio composition, with 72% in outpatient medical buildings, aligns with this trend. However, the broader REIT market has faced headwinds from rising interest rates, which can increase borrowing costs and impact property valuations, potentially contributing to the increased debt and impairment charge observed.

Comparison to Industry Standards

• The 95.2% occupancy rate is generally considered strong within the healthcare REIT sector, often comparable to or exceeding industry averages which typically range from 90-95% for medical office buildings.
• A weighted average lease term of 5.3 years is moderate; some healthcare REITs aim for longer terms to ensure stable cash flows, while others might accept shorter terms for flexibility in re-leasing at potentially higher market rates.
• The Net Debt / Annualized Adjusted EBITDAre of 6.9x is on the higher side compared to some well-capitalized healthcare REITs, which often target leverage ratios in the 5.0x to 6.0x range, indicating a more leveraged balance sheet.
• The 2.7% same-store cash NOI growth is positive but might be considered modest depending on market conditions and rent escalations compared to peers who might report higher growth in strong markets.
• The significant net loss and property impairment contrast with some industry leaders who have maintained profitability despite market challenges, suggesting specific asset-level or operational issues for Global Medical REIT.

Stakeholder Impact

• Shareholders: Negative impact due to the reported net loss, decreased diluted EPS, and increased leverage, which could affect dividend sustainability and share price.
• Creditors: Increased leverage ratios (Net Debt / Annualized Adjusted EBITDAre at 6.9x) suggest a higher risk profile, potentially impacting future borrowing costs or access to capital.
• Employees: No direct impact mentioned, but poor financial performance could lead to future operational adjustments.

Key Dates

Recommendation

The significant net loss, driven by a substantial property impairment, and the notable increase in leverage ratios (Net Debt / Annualized Adjusted EBITDAre rising to 6.9x) are strong negative signals. While some operating metrics like same-store NOI growth and occupancy are positive, they are insufficient to offset the deteriorating bottom line and increased financial risk. The company's ability to generate consistent profits is questionable given the impairment, and higher debt levels could constrain future growth and increase sensitivity to interest rate fluctuations. A seasoned investor would likely view these results as a clear indication of fundamental challenges and increased risk, warranting a 'sell' recommendation.

Keywords

Global Medical REIT, GMRE, REIT, Medical Real Estate, Healthcare REIT, Q3 2025 Earnings, Net Loss, EBITDAre, Same-Store NOI, Occupancy, Debt, Leverage, Property Impairment, Outpatient Medical, Inpatient Rehabilitation